Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Colorcon
McKesson
Teva
Fuji
Merck
Johnson and Johnson
QuintilesIMS

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00311155 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension Completed Sankyo Pharma Gmbh Phase 4 This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00649389 Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension Completed Daiichi Sankyo Inc. Phase 3 To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure.
NCT00791258 A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure Completed Integrium Phase 4 The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
NCT00791258 A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure Completed Daiichi Sankyo Inc. Phase 4 The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
NCT00890591 Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension Completed Daiichi Sankyo Inc. Phase 4 In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Condition Name

Condition Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention Trials
Essential Hypertension 4
Hypertension 2
Healthy Subjects 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Intervention Trials
Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Trials by Country

Trials by Country for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location Trials
United States 69
Italy 2
Germany 2
Netherlands 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Location Trials
Kansas 2
South Carolina 2
Kentucky 2
Maryland 2
Michigan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor Trials
Daiichi Sankyo Inc. 4
Torrent Pharmaceuticals Limited 2
Integrium 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Julphar
Baxter
Cerilliant
Covington
Merck
QuintilesIMS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.